Evidence map›Paper›PMID 27246982›Full record

ArticleOncotarget2016

Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.

Laudine Communal, Myriam Vilasco, Justine Hugon-Rodin, Aurélie Courtin, Najat Mourra, Najiba Lahlou, Morwenna Le Guillou, Muriel Perrault de Jotemps, Marie-Pierre Chauvet, Marc Chaouat and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Responsiveness ofCancer prevention research (Philadelphia, Pa.) · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Laudine CommunalUMRS 1007, Saints Pères, Paris Descartes University, Paris, France.
Myriam VilascoUMRS 1007, Saints Pères, Paris Descartes University, Paris, France.
Justine Hugon-RodinUMRS 1007, Saints Pères, Paris Descartes University, Paris, France.
Aurélie CourtinUMRS 1007, Saints Pères, Paris Descartes University, Paris, France.
Najat MourraService d'Anatomie et Cytologie Pathologiques, AP-HP, Hôpital Saint-Antoine, Paris, France.
Najiba LahlouService de Biologie Hormonale, Paris Descartes University, AP-HP, Hôpital Cochin, Paris, France.
Morwenna Le GuillouCNRS UMR8200 Gustave Roussy, Stabilité génétique et Oncogénèse, Paris-Saclay University, Villejuif, France.
Muriel Perrault de JotempsService de Chirurgie Plastique et Reconstructrice, Clinique Hartmann, Neuilly sur Seine, France.
Marie-Pierre ChauvetDépartement de Sénologie, Centre Oscar Lambret, Lille, France.
Marc ChaouatService de Chirurgie Plastique Reconstructrice et Esthétique et Chirurgie des Brûlés, Denis Diderot University, AP-HP, Hôpital Saint-Louis, Paris.
Pascal PujolCentre Hospitalier Universitaire, Montpellier University, Montpellier, France.
Jean FeunteunCNRS UMR8200 Gustave Roussy, Stabilité génétique et Oncogénèse, Paris-Saclay University, Villejuif, France.
Suzette DelalogeBreast Cancer Group, Gustave Roussy Cancer Campus, Villejuif, France.
Patricia ForgezUMRS 1007, Saints Pères, Paris Descartes University, Paris, France.
Anne GompelUMRS 1007, Saints Pères, Paris Descartes University, Paris, France.
Université Paris Cité · FRDélégation Paris 5 · FRAssistance Publique – Hôpitaux de Paris · FRCentre National de la Recherche Scientifique · FRCentre Oscar Lambret · FRClinique Hartmann · FRInstitut Gustave Roussy · FRStabilité génétique et oncogenèse · FRUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Women with inherited BRCA1 mutations have an elevated risk (40-80%) for developing breast and ovarian cancers. Reproductive history has been reported to alter this risk, suggesting a relationship between ovarian hormone signaling and BRCA1-related tumor development. BRCA1 interactions with estrogen receptor (ER) and progesterone receptor (PR) signaling were previously described in human breast cancer cell lines and mouse models. However, few studies have examined the effect of ovarian hormone regulation in normal human breast tissues bearing a heterozygous BRCA1 mutation. This study compares the proliferation level (Ki67) and the expression of ER, PR, and of the PR target gene, fatty acid synthase (FASN), in histologically normal breast tissues from women with BRCA1 mutations (BRCA1+/mut, n=23) or without BRCA1 mutations (BRCA1+/+, n=28). BRCA1+/mut tissues showed an increased proliferation and impaired hormone receptor expression with a marked loss of the PR isoform, PR-B. Responses to estradiol and progesterone treatments in BRCA1+/mut and BRCA1+/+ breast tissues were studied in a mouse xenograft model, and showed that PR and FASN expression were deregulated in BRCA1+/mut breast tissues. Progesterone added to estradiol treatment increased the proliferation in a subset of BRCA1+/mut breast tissues. The PR inhibitor, ulipristal acetate (UPA), was able to reverse this aberrant progesterone-induced proliferation. This study suggests that a subset of women with BRCA1 mutations could be candidates for a UPA treatment as a preventive breast cancer strategy.

Indexed as

Genes, BRCA1MutationAdultAnimalsBreastBreast NeoplasmsCell Line, TumorCell ProliferationEstradiolFemaleHumansMiceMiddle AgedNorpregnadienesReceptors, EstrogenReceptors, ProgesteroneEstradiolNorpregnadienesReceptors, EstrogenReceptors, Progesteroneulipristal acetateBRCA1breast cancerovarian hormonespreventionulipristal acetate

Identifiers

PMID27246982
PMCPMC5216725
OpenAlexW2397302835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.